Q1 Scientific, a Co Waterford-based provider of stability storage services for the pharma, medical device and life science industries, has been acquired by Cambrex, a US contract pharma company.
New Jersey-based Cambrex, which is what is known as a contract development and manufacturing organisation, said stability storage and testing was a “critical component” of drug development and the commercialisation of new therapies.
Q1 Scientific chief executive Stephen Delaney said:
“We’re pleased to join Cambrex as we continue to provide leading stability storage services to our current customers. With Cambrex’s scientific expertise and scale, we’ll be able to accelerate our growth and offer an integrated suite of analytical services, providing a full range of market-leading solutions for our customers.”
Cambrex chief executive Tom Loewald added:
“Q1 Scientific brings world-class capabilities to our ever-expanding portfolio of outsourced pharmaceutical services. This acquisition is a natural extension of our current offerings that will broaden and increase our expertise in this critical area, as well as our footprint in the European market.”
The company’s 1,860sq m (20,000sq ft) facility in Co Waterford is validated to meet the specific storage requirements of any pharma projects, with options from -80 degrees storage up to 50+ degrees, with a full range of humidity control. It has almost 40 walk-in stability storage chambers, reach-in freezers and stability units, and ultra-low temperature freezers for biologic therapies. It also provides sample management and transport services.